Crossmark

FAM168B identified as a novel candidate target for chimeric antigen receptor T cell-based cancer therapy

Crossref DOI link: https://doi.org/10.1007/s12672-025-03876-3

Published Online: 2026-01-27

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Pramanik, Subrata https://orcid.org/0000-0003-3328-6239
Thaker, Manisha https://orcid.org/0000-0001-9909-9909
Inoue, Noriko

Kim, Pok-Son https://orcid.org/0000-0002-2261-8712
Kutzner, Arne https://orcid.org/0000-0001-5061-6936
Manavalan, Arulmani https://orcid.org/0000-0002-3257-993X
Pramanik, Gopal https://orcid.org/0000-0002-9117-4887
Heese, Klaus https://orcid.org/0000-0002-0027-6993
License Information

Text and Data Mining valid from 2026-01-27

Version of Record valid from 2026-02-18
More Information

Article History

Received: 7 June 2025

Accepted: 13 October 2025

First Online: 27 January 2026

Declarations

:

: Not applicable.

: The authors declare no competing interests.